Background And Objectives: Mice sensitized with a chlamydial detergent extract and then genitally infected by Chlamydia trachomatis have increased genital inflammation characterized by elevated eosinophils, but do not have increased protective immunity. In contrast, mice infected previously by C. trachomatis show strong protective immunity. The authors studied interferon-gamma levels (associated with protective immunity) and interleukin-5 levels (the major cytokine responsible for eosinophilia).

Goals: To evaluate protective and nonprotective immune responses to chlamydial infection.

Study Design: The authors examined interferon-gamma and interleukin-5 levels in the genitalia during chlamydial genital infection among three groups of mice: extract-sensitized, sham-sensitized, and infected previously.

Results: Interferon-gamma levels peaked between 24 and 72 hours after chlamydial infection and then declined among all groups of mice. Overall, interleukin-5 levels increased throughout infection. Interleukin-5 levels apparently continued to increase over the 5-week period after primary infection.

Conclusions: Increased interferon-gamma levels were associated with an early response to chlamydial genital infection. Increased interleukin-5 levels were associated with a more persistent immune response.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00007435-199701000-00008DOI Listing

Publication Analysis

Top Keywords

interleukin-5 levels
20
genital infection
12
protective immunity
12
interferon-gamma levels
12
levels associated
12
interferon-gamma interleukin-5
8
chlamydia trachomatis
8
levels
8
chlamydial genital
8
groups mice
8

Similar Publications

Objectives: This study aims to use Mendelian randomisation to identify the causal relationship between a spectrum of 41 inflammatory cytokines and the development of oropharyngeal cancer.

Methods: This study investigated genetic variants that have been associated with oral and oropharyngeal cancer using data from a large GWAS. Inflammatory cytokine data were obtained from 8293 asymptomatic individuals.

View Article and Find Full Text PDF

Background: Uncontrolled severe eosinophilic chronic rhinosinusitis (eCRS) is associated with elevated levels of Th2 cells and raised immunoglobulin concentrations in nasal polyp tissue. eCRS is characterized by high eosinophilic infiltration and type 2 inflammation. Gαi1/3 proteins participate in allergic inflammation by regulating immune cells.

View Article and Find Full Text PDF

A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).

Ther Adv Respir Dis

January 2025

Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Section 2, Shipai Road, Beitou District, Taipei City 11217, Taiwan.

Background: REMIT is the first real-world study of mepolizumab effectiveness in patients with severe asthma (SA) in Taiwan.

Objectives: The primary objective evaluated changes in clinically significant exacerbations (CSEs; defined as use of oral corticosteroids (OCS) or emergency department (ED) visits and/or hospitalizations) in the 12 months pre- and post-mepolizumab treatment. Secondary objectives assessed changes in the number of CSEs requiring ED visits/hospitalizations and daily maintenance OCS (mOCS) dosage 12 months pre- and post-mepolizumab treatment.

View Article and Find Full Text PDF

GZMK-expressing CD8 T cells promote recurrent airway inflammatory diseases.

Nature

January 2025

Laboratory of Dynamic Immunobiology, Institute for Immunology, Tsinghua University, Beijing, China.

Inflammatory diseases are often chronic and recurrent, and current treatments do not typically remove underlying disease drivers. T cells participate in a wide range of inflammatory diseases such as psoriasis, Crohn's disease, oesophagitis and multiple sclerosis, and clonally expanded antigen-specific T cells may contribute to disease chronicity and recurrence, in part by forming persistent pathogenic memory. Chronic rhinosinusitis and asthma are inflammatory airway diseases that often present as comorbidities.

View Article and Find Full Text PDF

Mepolizumab in patients with lymphoid variant hypereosinophilic syndrome: a multi-center prospective study.

J Allergy Clin Immunol

January 2025

Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles, Brussels, Belgium.

Background: Hypereosinophilic syndrome (HES) is characterized by blood and tissue hypereosinophilia causing organ damage and/or dysfunction. Mepolizumab, an anti-IL-5 antibody, has recently been approved in this indication. In lymphoid variant (L-)HES, eosinophil expansion is driven by IL-5-producing clonal CD3CD4 T cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!